Three infants who presented with severe peanut and cashew allergies capable of triggering anaphylaxis have achieved complete, sustained tolerance and can now eat these nuts freely without restrictions or medications. The breakthrough comes from a specialized protocol called KIC-IT (Keep Introducing Consistently to Induce Tolerance) that begins with treating eczema, then introduces raw nuts before roasted versions, allowing the immune system to build tolerance during infancy when it is most adaptable. What Makes This Protocol Different From Previous Allergy Treatments? For decades, allergists advised parents to avoid introducing common allergens like peanuts until children were older, believing delayed exposure would prevent allergies from developing. This approach backfired. Research published in 2015 showed that early introduction of peanuts actually reduced allergy risk, leading to major guideline changes by the American Academy of Pediatrics (AAP) and the National Institute of Allergy and Infectious Diseases (NIAID) in 2017. However, the KIC-IT protocol takes early introduction a step further by using a specific sequence and addressing underlying inflammation. The three infants treated at the Kado Clinic ranged from 6 months to 1 year old when they began the protocol. All three had documented anaphylaxis reactions and significant eczema, with body surface areas affected ranging from 30% to 60%. Rather than simply avoiding the allergen or relying on emergency epinephrine auto-injectors, the clinicians used a structured approach that fundamentally changed how these children's immune systems responded to nuts. "These are kids who showed anaphylaxis at 6 months, and instead of just saying 'You get an EpiPen' or 'You have to avoid it,' we found a way to allow a sustained tolerance so that we could change the rest of their life," said Dr. Rachel Kado, allergist and immunologist at the Kado Clinic. Dr. Rachel Kado, Allergist and Immunologist, Kado Clinic How Does the KIC-IT Protocol Work Step by Step? - Eczema Control First: Before any allergen exposure, the protocol requires complete clearance of atopic dermatitis using a proprietary non-steroidal CB2 receptor agonist phytolipid ceramide-rich cream. This step is critical because eczema creates systemic inflammation that lowers the threshold for allergic reactions. - Raw Nut Introduction: Once eczema is controlled, infants receive their first dose of raw peanuts or cashews in the clinic, with 20-minute observation periods between doses. If symptoms appear but resolve within 20 minutes, dosing continues; if not, the challenge ends for that day. - Home Dosing Phase: After establishing a tolerated dose in the clinic, caregivers administer the same dose at home daily. Once the infant completes 3 consecutive days without symptoms, the family returns to the clinic for a dose escalation. - Transition to Roasted Nuts: This process continues until the infant can tolerate three whole raw peanuts or cashews. Then the entire process repeats with roasted versions, which are more allergenic than raw nuts. Daily ingestion of roasted nuts continues for 3 years. - Unrestricted Consumption: By age 4 years, children achieve unrestricted consumption with no limits on how much they can eat. The key insight behind this sequence is that raw peanuts and cashews trigger less severe immune responses than roasted versions. Proteins with minimal processing result in reduced immediate IgE cross-linking (the antibody responsible for allergic reactions), while roasted nuts consolidate regulatory pathways during infancy when the immune system is most malleable. What Were the Actual Results for These Three Infants? The first infant, who presented with peanut allergy and severe eczema covering 60% of body surface area at 6 months, initially failed the LEAP (Learning Early About Peanut Allergy) study with hives, spitting up, and sneezing. Using the KIC-IT protocol, this infant experienced mild hives, spit up, and sneezed when first exposed to raw peanut but completed 3 symptom-free days and transitioned to roasted peanut by 8 months. By day 15 of roasted peanut consumption, the infant could eat three roasted African runner peanuts daily. Full tolerance to all forms of peanut was achieved by age 3 years, with free eating at age 4. The second infant, who presented with peanut allergy, 40% body surface area eczema, and egg allergy at 10 months, experienced four perioral hives after consuming 1/64th of a raw peanut initially. After 25 days of treatment, this infant was consuming three roasted African runner peanuts daily, which remained the maintenance dose through age 3 years. Full tolerance to all forms of peanut and free eating at age 4 were achieved. The third infant, with cashew allergy and 30% body surface area eczema, had no reaction to raw cashew at treatment start but experienced three to five perioral hives when introduced to roasted cashew at age 2 years. Doses increased to three roasted cashews as the maintenance dose, with full tolerance to all forms of cashew by age 4 years. "There was 100% of sustained tolerance at the 3-year follow-up with each of these infants," noted Morgan Schmidt, clinical research fellow at the Kado Clinic. Morgan Schmidt, Clinical Research Fellow, Kado Clinic Critically, none of the infants required medications during the protocol. This represents the first documented cases of infants achieving sustained, medication-free tolerance by consuming raw and then roasted allergens. Why Is Timing So Important for This Protocol? The success of the KIC-IT protocol hinges on the plasticity of the infant immune system between ages 6 and 11 months. During this window, the immune system is exceptionally adaptable and capable of developing tolerance rather than mounting allergic responses. Dr. Kado attributed the protocol's success to this critical developmental period, explaining that older children and adults have more rigid immune responses that are harder to reprogram. The researchers also emphasized that reaction thresholds can fall because of systemic inflammatory load, which is why eczema control is essential to the protocol's safety and success. By addressing the underlying skin barrier dysfunction and inflammation first, clinicians reduce the overall immune activation that would otherwise trigger allergic reactions. This approach contrasts sharply with traditional food allergy management, which relies on strict avoidance and emergency preparedness. Instead of teaching families to fear accidental exposure, the KIC-IT protocol actively trains the immune system to tolerate and eventually embrace the allergen. The researchers have indicated that the KIC-IT protocol is available for other allergy clinics to implement, and they are actively sharing white papers and detailed protocols with interested practitioners. They also expressed hope that prospective trials will validate the protocol's safety, efficacy, and generalizability across different patient populations.
